Sepiapterin
Small molecule
Evidence outlook
Approved: Phenylketonuria
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (2)
- Phenylketonuria (PKU), all ages and full spectrum of disease severity
- Treatment of hyperphenylalaninaemia (HPA) in adult and paediatric patients with phenylketonuria (PKU)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
EPIPHENY NCT06302348 · Phenylketonuria Registry: NCT06302348 | 3 | Mean Change From Baseline in Full-scale Intelligence Quotient (FSIQ) Wechsler Preschool and Primary Scale of Intelligence - Fourth Edition (WPPSI-IV) Score (Baseline, Year 2); Mean Change From Baseline in FSIQ Wechsler Intelligence Scale for Children - Fifth Edition (WISC-V) Score (Baseline, Year 2) 2031-02-28 | In progress: results expected 28 Feb 2031 | not yet graded | link ↗ |
View 1 more trial
NCT05099640 NCT05099640 · Phenylketonuria Following an open-label run-in phase that identified patients who responded to sepiapterin, those responders were randomized in a double-blind, placebo-controlled comparison of 110 patients. The primary endpoint, blood phenylalanine level, fell by 63% with sepiapterin versus essentially no change with placebo, a highly statistically significant difference (p<0.0001). Registry: NCT05099640 | 3 | Part 2 Double-blind Phase: Mean Change From Baseline in Blood Phenylketonuria (Phe) Level to Weeks 5 and 6 (Averaged Over a 2-week Period) in Participants With Phe Reduction From Baseline ≥30% During Part 1 (Baseline, Weeks 5 and 6 (average of the 2-week period)); Part 2 Double-blind Phase: Percent Change From Baseline in Blood Phe Level to Weeks 5 and 6 (Averaged Over a 2-week Period) in Participants With Phe Reduction From Baseline ≥30% During Part 1 (Baseline, Weeks 5 and 6 (average of the 2-week period)) 2023-04-03 | Completed. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (3)
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Competitive landscape
Other Phenylalanine hydroxylase (PAH) drugs
Sapropterin Dihydrochloride (Kuvan). Compare all 2 Phenylalanine hydroxylase (PAH) drugs
1 other tracked programme targets this mechanism, none of them ahead of this one.
This drug's own stage for Phenylketonuria: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Sepiapterin: this drug | Approved | Small molecule | Phenylalanine hydroxylase (PAH) | Reliable signal | No reviewed efficacy summary in this indication | |
| Pegvaliase (PALYNZIQ) | Approved | Protein / enzyme therapeutic | Phenylalanine ammonia lyase (enzyme substitution) | Weak signal | Featured results are safety only in this race | |
| Sapropterin Dihydrochloride (Kuvan) | Approved | Small molecule | Phenylalanine hydroxylase (PAH) | Reliable signal | NCT00104247: Change in Blood Phenylalanine Levels From Baseline to Week 6. (baseline to week 6): Sapropterin Dihydrochloride — Baseline Blood Phe Level: 843 micromole per liter (Standard Deviation 300); Week 6 Blood Phe Level: 607 micromole per liter (Standard Deviation 377); Mean Change in Blood Phe from Baseline to Week 6: -239 micromole per liter (Standard Deviation 38) | Placebo — Baseline Blood Phe Level: 888 micromole per liter (Standard Deviation 323); Week 6 Blood Phe Level: 891 micromole per liter (Standard Deviation 348); Mean Change in Blood Phe from Baseline to Week 6: 6 micromole per liter (Standard Deviation 36) NCT00272792: Phenylalanine supplement tolerated at week 10: sapropterin 20.9 (SD 15.4) vs placebo 2.9 (SD 4.0) mg/kg/day; mean difference 17.7 (SE 4.5) mg/kg/day, P<.001 (n=33 and 12) (Trefz et al., J Pediatr 2009). | |
| BEAM-304 | —(overall) | Gene therapy / editing | PAH gene (phenylalanine hydroxylase) | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Sepiapterin to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2031 (1)
February 2031 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent